Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lexicon Pharmaceutcl (LXRX)

Lexicon Pharmaceutcl (LXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 505,125
  • Shares Outstanding, K 363,399
  • Annual Sales, $ 31,080 K
  • Annual Income, $ -200,400 K
  • EBIT $ -67 M
  • EBITDA $ -64 M
  • 60-Month Beta 0.96
  • Price/Sales 16.37
  • Price/Cash Flow N/A
  • Price/Book 4.23

Options Overview Details

View History
  • Implied Volatility 161.36% (+14.23%)
  • Historical Volatility 80.00%
  • IV Percentile 34%
  • IV Rank 13.76%
  • IV High 558.03% on 02/24/25
  • IV Low 98.07% on 05/20/25
  • Expected Move (DTE 10) 0.2125 (16.04%)
  • Put/Call Vol Ratio 0.11
  • Today's Volume 510
  • Volume Avg (30-Day) 730
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 36,391
  • Open Int (30-Day) 35,938
  • Expected Range 1.1125 to 1.5375

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.07
  • Number of Estimates 3
  • High Estimate -0.07
  • Low Estimate -0.08
  • Prior Year -0.09
  • Growth Rate Est. (year over year) +22.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2500 +4.80%
on 11/10/25
1.6400 -20.12%
on 11/12/25
+0.0600 (+4.80%)
since 11/07/25
3-Month
1.0600 +23.58%
on 09/17/25
1.6600 -21.08%
on 10/10/25
+0.1800 (+15.93%)
since 09/09/25
52-Week
0.2800 +367.86%
on 03/03/25
1.6600 -21.08%
on 10/10/25
+0.5739 (+77.96%)
since 12/09/24

Most Recent Stories

More News
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum

THE WOODLANDS, Texas, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced clinical data on adipose tissue distribution in non-diabetic patients treated with sotagliflozin...

LXRX : 1.3100 (-5.76%)
Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences

THE WOODLANDS, Texas, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Piper Sandler...

LXRX : 1.3100 (-5.76%)
Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference

THE WOODLANDS, Texas, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Jefferies 2025...

LXRX : 1.3100 (-5.76%)
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

THE WOODLANDS, Texas, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that new sotagliflozin clinical data was presented at the AHA Annual Scientific...

LXRX : 1.3100 (-5.76%)
Lexicon: Q3 Earnings Snapshot

Lexicon: Q3 Earnings Snapshot

LXRX : 1.3100 (-5.76%)
Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates

FDA End-of-Phase 2 meeting for pilavapadin in DPNP to be held by year-end All IND-enabling studies of LX9851 for obesity completed and submitted to licensee Novo Nordisk Site initiation...

LXRX : 1.3100 (-5.76%)
Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association’s Sessions 2025 in New Orleans

THE WOODLANDS, Texas, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.   (Nasdaq: LXRX) today announced that data from three studies of sotagliflozin will be presented during upcoming...

LXRX : 1.3100 (-5.76%)
Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

THE WOODLANDS, Texas, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its third quarter 2025 financial results on Thursday, November...

LXRX : 1.3100 (-5.76%)
Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit

– Results support advancement of 10 mg dose into Phase 3 development – – End-of-Phase 2 meeting request accepted by U.S. FDA; partnership discussions progressing – THE WOODLANDS, Texas,...

LXRX : 1.3100 (-5.76%)
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain

THE WOODLANDS, Texas, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Yesterday,  Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX) hosted and participated in a roundtable discussion with experts to explore how to...

LXRX : 1.3100 (-5.76%)

Business Summary

Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones....

See More

Key Turning Points

3rd Resistance Point 1.5932
2nd Resistance Point 1.5365
1st Resistance Point 1.4633
Last Price 1.3100
1st Support Level 1.3334
2nd Support Level 1.2767
3rd Support Level 1.2035

See More

52-Week High 1.6600
Last Price 1.3100
Fibonacci 61.8% 1.1328
Fibonacci 50% 0.9700
Fibonacci 38.2% 0.8072
52-Week Low 0.2800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar